TriangleAlirocumab (NCT06385262)
Alirocumab trial for Non Small Cell Lung Cancer (NCT06385262). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with untreated, resectable non-small-cell lung cancer meeting stage IB–III (N0–2) criteria. Known EGFR, ALK or ROS1 alterations are excluded.
The idea: add alirocumab to platinum chemotherapy and cemiplimab before surgery. Alirocumab blocks PCSK9; researchers propose this could make cancer cells more visible to immune cells. Cemiplimab blocks PD-1. Treatment includes three chemotherapy/immunotherapy cycles, with alirocumab every four weeks. The comparison arm closed in July 2026. Researchers assess tissue and safety.
This phase 2 study plans 63 patients. Neal Ready leads at Duke in Durham, the recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.